Department of Pathology,1 Program in Cell and Molecular Biology, University of Michigan, Ann Arbor, Michigan 481092
Received 30 July 2002/ Returned for modification 21 August 2002/ Accepted 13 December 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In addition to their potential roles in DNA repair pathways, the nuclear BRCT domain proteins have also been linked to gene activation (22). In Xenopus laevis, the PTIP-related protein Swift was identified on the basis of its ability to bind the Smad2 transcription factor and accentuate Smad2-dependent transcription (20). At the time of gastrulation, Smad2 mediates gene activation in response to signaling by the secreted transforming growth factor ß family member Activin. PTIP also interacts with the Pax family of transcription regulators (13) and, at least in one case, is able to inhibit transactivation of the glucagon promoter in pancreatic cells (7). PTIP and Swift contain two amino-terminal BRCT domains, a glutamine-rich region, and three and four carboxy-terminal BRCT domains, respectively.
In order to discern the role of PTIP in development, we generated a null allele in mice by homologous recombination. PTIP mutants show greatly enhanced cell death prior to and at the time of gastrulation and were severely retarded thereafter. In PTIP-null mutants, cells replicate DNA but exhibit DNA damage, as evidenced by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay. Embryonic fibroblasts or inner cell mass cells fail to grow out from PTIP-null embryos in vitro. In PTIP mutants, cells exhibit suppressed levels of phospho-histone H3, which is required for proper chromatin condensation. In cells entering mitosis, chromatin condensation appears to be affected, with few well-demarcated chromosomes evident. By day 8.5 of embryonic development (E8.5), few cells are seen in mitosis. The data imply that PTIP has an essential role in cell division after S phase and before completion of mitosis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
BrdU labeling and TUNEL assay. Pregnant female mice were injected intraperitoneally with bromodeoxyuridine (BrdU; Sigma) in phosphate-buffered saline (PBS) at a concentration of 3 mg/100 g of body mass. Mice were sacrificed after 2 or 4 h. Embryos were fixed overnight in paraformaldehyde, dehydrated, and embedded in paraffin. Sections were cut at 8 µm, deparaffinized, rehydrated, and permeabilized with 2 N HCl-0.5% Triton X-100-PBS for 10 min. Anti-BrdU (Sigma) was diluted 1:100 in PBS-0.5% Tween 20 (PBST) containing 2% goat serum and incubated for 1 h at room temperature. Slides were washed three times in PBST and incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibodies (Sigma) for 1 h. Slides were washed three times in PBST and mounted with Gelvatol. The TUNEL reaction was performed with the FITC-labeled Apotag kit (Boehringer Mannheim, Inc.) in accordance with the manufacturer's protocol, except that the permeabilization time was increased to 20 min.
Protein analysis. Embryos were dissected free from the yolk sac, which was saved for DNA extraction, and lysed in 100 ml of PK lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1 mM Na vanadate, 50 mM NaF, 500 nM okadaic acid, 1x protease inhibitor cocktail [Roche]). Approximately 20 µg of total protein was boiled in 1x sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer and subjected to SDS-10% PAGE. After transfer to polyvinylidene fluoride membrane, membranes were blocked with 5% milk in TBS and incubated for 3 h with 1 µg of antibodies against P-histone H3 or acetyl-histone H3 (Upstate Biotech) per ml in 1x TBS-1% milk-0.1% Tween 20 (TBSTM). Membranes were washed three times for 15 min (each time) in TBSTM and incubated with horseradish peroxidase-conjugated anti-mouse antibodies (Amersham Inc.). Membranes were washed three times in TBSTM and two times in TBS for 15 min (each time) and visualized by chemiluminescence in accordance with the manufacturer's (NEN) protocol.
Cell cycle expression. To determine the expression profile of PTIP during the cell cycle, we utilized both NIH 3T3 cells and wild-type primary mouse embryo fibroblasts (MEFs). Cells were plated at 5 x 105/60-mm-diameter plate and serum starved for 48 h in Dulbecco modified Eagle medium (DMEM) with 0.5% fetal calf serum. Quiescent cells were then activated with either 10% fetal calf serum, for NIH 3T3 cells, or 20% fetal calf serum, for MEFs. At various time points after serum addition, cells were rinsed in PBS and scraped. Equal numbers of cells were lysed in PK lysis buffer, and proteins were analyzed by SDS-PAGE and Western blotting.
Blastocyst outgrowths. Four- to 5-week-old females were injected with 5 IU of pregnant mare serum gonadotropin and 2 days later with 5 IU of human chorionic gonadotropin. The blastocysts were flushed out of the uterine horns 3 days after vaginal plug detection. Blastocysts were cultured on gelatinized 96-well round-bottom plates in DMEMD supplemented with 20% fetal calf serum. For radiation sensitivity assays, blastocysts were exposed to 2 Gy of ionizing radiation at day 0 and cultured for 7 days. Cells were stained with Hoechst fluorescent dye and counted.
Immunostaining.
E7.5 and E8.5 embryos were dissected free of the decidua, and a small piece of the amniotic membrane was used to genotype the mutants by PCR using primers specific for the neo cassette and primers specific for the wild-type PTIP allele. Embryos were fixed in 4% paraformaldehyde-PBS at 4°C, dehydrated in graded ethanol, and embedded in paraffin. Sections were cut at 3 to 4 µm. After dewaxing and rehydration, sections were boiled for 8 min in a pressure cooker with a 1:100 dilution of antigen unmasking solution (Vector Laboratories). Sections were washed in PBS and incubated with antibodies against P-histone H3 (Upstate Biotech),
-tubulin (Sigma), or
-tubulin (Sigma) in a buffer consisting of PBS, 0.1% Tween 20, and 2% goat serum. After incubation for 2 h at room temperature, sections were washed two times for 10 min (each time) in PBS-0.1% Tween 20 and incubated with FITC- or tetramethyl rhodamine isothiocyanate-conjugated secondary antibodies for 1 h. Sections were washed two times and covered with Gelvatol containing 0.2% 1,4-diazabicyclo(2,2,2)octane. Photomicrographs were taken with a Nikon ES800 fluorescent micrograph and a Spot digital camera.
| RESULTS |
|---|
|
|
|---|
|
The size and condition of PTIP mutant embryos indicated a lack of proliferation or enhanced cell death. To further characterize the phenotype of PTIP mutants, embryos were examined at E7.5 and E8.5 for cell proliferation and apoptosis. Prior to sacrifice of the female, BrdU was injected intraperitoneally to label dividing cells. Embryos were embedded in paraffin and sectioned for histology, for immunostaining with anti-BrdU antibodies, and for cell death staining by the TUNEL assay. At E7.5 (Fig. 2), PTIP-/- embryos were usually discernible on the basis of their smaller phenotype. While normal embryos had three well-defined cavities, the amniotic, the exocoelomic, and the ectoplacental, PTIP-null mutants lacked a clearly defined amnion (Fig. 2A). The ectoplacental cone was well developed in PTIP-null embryos, but the egg cylinder was about half as long as that of a normal E7.5 embryo. PTIP-null embryos exhibited BrdU incorporation at levels equal to that of the wild type, indicating that cell cycle progression occurred at least to S phase (Fig. 2C and F). BrdU-positive cells were counted and compared to the total number of nuclei observed on given sections. On average, about 63% ± 7% of the cells within the embryonic ectoderm were positive for anti-BrdU staining in the wild type or PTIP mutants at E7.5. However, TUNEL staining for apoptosis revealed differences between normal embryos and PTIP-null mutants (Fig. 2B and E). PTIP mutants showed significant cell death, particularly within the embryonic ectodermal layer. Strikingly, the extraembryonic and ectoplacental tissues did not exhibit much apoptosis at this stage. Wild-type embryos showed little apoptosis at E7.5, except in the uterine wall. While the TUNEL assay is generally used to mark apoptotic cells, it is really a measure of free DNA ends. During normal apoptosis, nuclear condensation and DNA fragmentation are closely linked. Strikingly, many PTIP-null nuclei stained positive in the TUNEL assay even before nuclear condensation was evident, whereas wild-type TUNEL-positive nuclei were almost always pyknotic (Fig. 2G and H). At E8.5, PTIP-null embryos were developmentally arrested and disorganized (Fig. 3A and D). Neural plate and mesodermal tissues could be identified morphologically, indicating that some aspects of gastrulation had occurred. At E8.5, apoptosis was more widespread than at E7.5 in PTIP-null mutants and its level was particularly high in the embryo proper (Fig. 3B and E). BrdU-positive cells were abundant in the wild-type embryos, representing about 52% ± 9% of the total nuclei (Fig. 3F). In the PTIP-null mutants, BrdU-positive cells were only observed in regions that did not exhibit much apoptosis (Fig. 3C). Thus, PTIP homozygous null embryos were smaller and disorganized because of an extremely high rate of cell death, starting in the embryonic ectoderm prior to gastrulation and continuing into later developmental stages.
|
|
|
|
- and
-tubulin and condensed chromatin was counterstained with 4',6'-diamidino-2-phenylindole (DAPI) or propidium iodide (Fig. 5). While many PTIP-/- cells incorporated BrdU at E7.5, the number of cells with condensed chromatin was reduced at E7.5 and severely limited by E8.5. On average, approximately 2.5% ± 1% of the cells of PTIP mutants showed some condensed chromatin at E7.5 whereas 6.7% ± 0.8% of the cells of wild-type embryos exhibited condensed chromatin. On histological sections, many cells in a wild-type E7.5 embryo could be seen in mitosis, as evidenced by segregating chromosomes, well-defined centrosomes, and an organized microtubular network (Fig. 5A and B). Although PTIP-/- mutants showed condensed chromatin, their chromosomes were not well demarcated, few centrosomes were visible, and the microtubular network was poorly elaborated (Fig. 5C to F).
|
|
| DISCUSSION |
|---|
|
|
|---|
Our analysis indicates that at E7.5, PTIP mutant cells are into and possibly through S phase and replicating DNA. In the TUNEL assay, significant amounts of free DNA ends are seen in PTIP mutants within the embryo proper at E7.5. While some apoptosis occurs in wild-type embryos, the labeled nuclei are generally pyknotic. Many PTIP-null nuclei are TUNEL positive even before nuclear condensation has occurred, suggesting that DNA breakage or failure to repair DNA strands may be an integral part of the null phenotype. Strikingly, cell death occurs first within the embryonic ectoderm, which generates the embryo proper. On the basis of BrdU labeling, the embryonic ectoderm proliferates more rapidly than the extraembryonic tissues and may thus be more sensitive to DNA damage. Perhaps because of the rapid rate of cell division, the embryonic ectoderm, prior to and at the time of gastrulation, appears to be particularly sensitive to mutations in the DNA damage checkpoint pathways. Mutations in the genes encoding the Chk1 kinase (16, 21) and its upstream activator, ATR (1, 4), lead to DNA damage and cell death by E7.5. As with our PTIP mutants, ATR and Chk1 mutants also do not exhibit inner cell mass outgrowths when blastocysts are placed in culture. Complete BRCA1-null mutants (6, 15) have similar early lethal phenotypes at around E6.5, although embryos with deletions of just the BRCT domains of BRCA1 develop somewhat further to the head fold stage at E9.5 (8). The similarity of the PTIP and Chk1/ATR mutant phenotypes led us to examine whether PTIP mutants also fail to activate the G2/M checkpoint upon UV irradiation. However, experiments with UV-irradiated blastocysts grown for 4 to 6 h in culture did not conclusively demonstrate a role for PTIP in checkpoint control at this stage (data not shown). PTIP mutant trophoblast cells did show increased sensitivity to ionizing radiation, similar to what has been observed for Brca2 (19) and the mouse rad51 homologue (14). While these data are consistent with a role for PTIP in the damage control pathway, they do not allow us to assign a specific function.
Phosphorylation of histone H3 by the aurora-like kinases is essential for chromatin condensation and entry into mitosis (3, 9). Thus, the suppression of histone H3 phosphorylation observed in PTIP mutants can certainly prevent progression through mitosis. However, it is unclear whether this is a direct effect of loss of PTIP function or whether DNA damage or other upstream events result in the progressively lower levels of phospho-histone H3. Defects in heterochromatin condensation have also been observed in Drosophila mus101 gene mutants (23), a multiple BRCT domain-encoding gene with some similarity to topoisomerase binding protein 1 (TopBP1), yeast Rad4/cut5, and mammalian PTIP. mus101 mutants are also hypersensitive to DNA-damaging agents and exhibit genetic instabilities. The PTIP-null phenotype stands in contrast to that of mutants blocked from exit from mitosis, such as Sak polo-like kinase mutants (10), in which more phospho-histone H3-positive cells accumulate. However, Sak-null mutants also show apoptosis and developmental arrest at the time of gastrulation. Thus, in PTIP mutants, mitotic arrest appears to occur at a stage in the cell cycle prior to that regulated by the Sak kinase. Our observations are consistent with a potential role for PTIP in the regulation of DNA repair, as has been reported for the yeast Crb2 protein. The BRCT domain protein Crb2 is necessary for topoisomerase III-mediated recombination repair in G2 (2). Failure to initiate DNA repair can result in genetic instability, fragmented chromosomes, and cell death. If PTIP did function in DNA repair, one might predict its expression to be regulated during the cell cycle. We see no diminution of PTIP expression in quiescent cells or increased expression at S or G2 phase. However, our experiments did not address the possibility of posttranslational modifications during the cell cycle.
The phenotype of PTIP-null mutants does not provide much insight into the potential for PTIP to mediate transcription regulation, as suggested by the interaction with Pax proteins and the binding of Xenopus Swift to Smad2. While the disorganized PTIP mutant E8.5 embryos vary greatly in the degree of differentiation, we can see neural tissue, head folds, and even somites in some embryos, suggesting that gastrulation can begin. We have also crossed the PTIP-null allele into Smad2 mutants. A fraction of Smad2 heterozygotes have gastrulation and other patterning defects (17). However, we have not observed any increase in developmental abnormalities in Smad2/PTIP double heterozygotes, although this negative result does not disprove an interaction.
While our data are suggestive of a role for PTIP in DNA repair, the potential for PTIP to function as a transcription activator through the conserved BRCT domains is not clear. Although the potential for PTIP to control elements of the cell cycle regulatory or DNA repair machinery at the transcriptional level is consistent with all of the data, it seems unlikely that PTIP functions as a tissue-specific activator during a time point in development, as most mutant embryos, while disorganized and developmentally retarded, do show evidence of gastrulation and differentiation. In summary, the mutant analysis presented in this report indicates that PTIP is likely to play an essential role in cell proliferation, perhaps as a component of the DNA damage/repair pathways. How mammalian PTIP functions at the biochemical level remains to be defined.
| ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grants DK54740 and DK54723 to G.R.D. M.J.P. is supported by National Institutes of Health training grant HD07505.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Caspari, T., J. M. Murray, and A. M. Carr. 2002. Cdc2-cyclin B kinase activity links Crb2 and Rqh1-topoisomerase III. Genes Dev. 16:1195-1208.
3. Crosio, C., G. M. Fimia, R. Loury, M. Kimura, Y. Okano, H. Zhou, S. Sen, C. D. Allis, and P. Sassone-Corsi. 2002. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 22:874-885.
4. de Klein, A., M. Muijtjens, R. van Os, Y. Verhoeven, B. Smit, A. M. Carr, A. R. Lehmann, and J. H. Hoeijmakers. 2000. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10:479-482.[CrossRef][Medline]
5. Esashi, F., and M. Yanagida. 1999. Cdc2 phosphorylation of Crb2 is required for reestablishing cell cycle progression after the damage checkpoint. Mol. Cell 4:167-174.[CrossRef][Medline]
6. Hakem, R., J. L. de la Pompa, C. Sirard, R. Mo, M. Woo, A. Hakem, A. Wakeham, J. Potter, A. Reitmair, F. Billia, E. Firpo, C. C. Hui, J. Roberts, J. Rossant, and T. W. Mak. 1996. The tumor suppressor gene Brca1. is required for embryonic cellular proliferation in the mouse. Cell 85:1009-1023.[CrossRef][Medline]
7. Hoffmeister, A., A. Ropolo, S. Vasseur, G. V. Mallo, H. Bodeker, B. Ritz-Laser, G. R. Dressler, M. I. Vaccaro, J. C. Dagorn, S. Moreno, and J. L. Iovanna. 2002. The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. J. Biol. Chem. 277:22314-22319.
8. Hohenstein, P., M. F. Kielman, C. Breukel, L. M. Bennett, R. Wiseman, P. Krimpenfort, C. Cornelisse, G. J. van Ommen, P. Devilee, and R. Fodde. 2001. A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 20:2544-2550.[CrossRef][Medline]
9. Hsu, J. Y., Z. W. Sun, X. Li, M. Reuben, K. Tatchell, D. K. Bishop, J. M. Grushcow, C. J. Brame, J. A. Caldwell, D. F. Hunt, R. Lin, M. M. Smith, and C. D. Allis. 2000. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102:279-291.[CrossRef][Medline]
10. Hudson, J. W., A. Kozarova, P. Cheung, J. C. Macmillan, C. J. Swallow, J. C. Cross, and J. W. Dennis. 2001. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr. Biol. 11:441-446.[CrossRef][Medline]
11. Joyner, A. L. 1993. Gene targeting: a practical approach. Oxford University Press, Oxford, United Kingdom.
12. Koonin, E. V., S. F. Altschul, and P. Bork. 1996. Functional motifs. Nat. Genet. 13:266-268.[CrossRef][Medline]
13. Lechner, M. S., I. Levitan, and G. R. Dressler. 2000. PTIP, a novel BRCT domain-containing protein, interacts with Pax2 and is associated with active chromatin. Nucleic Acids Res. 28:2741-2751.
14. Lim, D.-S., and P. Hasty. 1996. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16:7133-7143.[Abstract]
15. Liu, C. Y., A. Flesken-Nikitin, S. Li, Y. Zeng, and W. H. Lee. 1996. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10:1835-1843.
16. Liu, Q., S. Guntuku, X. S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, L. A. Donehower, and S. J. Elledge. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev. 14:1448-1459.
17. Nomura, M., and E. Li. 1998. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393:786-790.[CrossRef][Medline]
18. Saka, Y., F. Esashi, T. Matsusaka, S. Mochida, and M. Yanagida. 1997. Damage and replication checkpoint control in fission yeast is ensured by interactions of Crb2, a protein with BRCT motif, with Cut5 and Chk1. Genes Dev. 11:3387-3400.
19. Sharan, S. K., M. Morimatsu, U. Albrecht, D. S. Lim, E. Regel, C. Dinh, A. Sands, G. Eichele, P. Hasty, and A. Bradley. 1997. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810.[CrossRef][Medline]
20. Shimizu, K., P.-Y. Bourillot, S. J. Nielsen, A. M. Zorn, and J. B. Gurdon. 2001. Swift is a novel BRCT domain coactivator of Smad2 in transforming growth factor ß signaling. Mol. Cell. Biol. 21:3901-3912.
21. Takai, H., K. Tominaga, N. Motoyama, Y. A. Minamishima, H. Nagahama, T. Tsukiyama, K. Ikeda, K. Nakayama, and M. Nakanishi. 2000. Aberrant cell cycle checkpoint function and early embryonic death in Chk1-/- mice. Genes Dev. 14:1439-1447.
22. Welcsh, P. L., M. K. Lee, R. M. Gonzalez-Hernandez, D. J. Black, M. Mahadevappa, E. M. Swisher, J. A. Warrington, and M. C. King. 2002. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl. Acad. Sci. USA 99:7560-7565.
23. Yamamoto, R. R., J. M. Axton, Y. Yamamoto, R. D. Saunders, D. M. Glover, and D. S. Henderson. 2000. The Drosophila mus101 gene, which links DNA repair, replication and condensation of heterochromatin in mitosis, encodes a protein with seven BRCA1 C terminus domains. Genetics 156:711-721.
24. Yarden, R. I., S. Pardo-Reoyo, M. Sgagias, K. H. Cowan, and L. C. Brody. 2002. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 30:285-289.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|